Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase i trial in patients with advanced solid tumors: A California Cancer Consortium trial

Cancer Chemotherapy and Pharmacology

Volumn 76, Issue 5, 2015, Pages 897-907

  Morgan, Robert J ^a   Synold, Timothy W ^a   Longmate, Jeffrey A ^a   Quinn, David I ^b   Gandara, David ^c   Lenz, Heinz Josef ^b   Ruel, Christopher ^a   Xi, Bixin ^a   Lewis, Michael D ^d,f   Colevas, A Dimitrios ^e,g   Doroshow, James ^a,e   Newman, Edward M ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EISAI RESEARCH INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f Edward P Evans Foundation   (United States)

^g STANFORD CANCER INSTITUTE   (United States)

Author keywords

Eribulin; Halichondrin B analog; Pharmacodynamics; Pharmacokinetics; Phase I trial

Indexed keywords

ALKALINE PHOSPHATASE; ERIBULIN; ANTINEOPLASTIC AGENT; FURAN DERIVATIVE; KETONE; TUBULIN MODULATOR;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DESQUAMATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG RESPONSE; ELIMINATION HALF-LIFE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOCYTE DIFFERENTIAL COUNT; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; LUNG CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA AND VOMITING; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; TANDEM MASS SPECTROMETRY; UROGENITAL TRACT TUMOR; VALIDATION STUDY; BLOOD; BREAST NEOPLASMS; CARCINOMA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG MONITORING; INTRAVENOUS DRUG ADMINISTRATION; LUNG NEOPLASMS; MIDDLE AGED; MULTICENTER STUDY; OVARIAN NEOPLASMS; SALVAGE THERAPY; UROLOGIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEBRILE NEUTROPENIA; FEMALE; FURANS; HUMANS; INJECTIONS, INTRAVENOUS; KETONES; LUNG NEOPLASMS; LYMPHOPENIA; MALE; MELANOMA; MIDDLE AGED; OVARIAN NEOPLASMS; SALVAGE THERAPY; TUBULIN MODULATORS; UROLOGIC NEOPLASMS;

EID: 84945452173     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2868-7     Document Type: Article

References (37)

1. Margolin K, Synold T, Longmate J, Doroshow JH (2001) Methodologic guidelines for the design of high-dose chemotherapy regimens. Biol Blood Marrow Transpl 7(8):414-432
2. Kraljevic S, Sedic M, Scott M, Gehrig P, Schlapbach R, Pavelic K (2006) Casting light on molecular events underlying anti-cancer drug treatment: what can be seen from the proteomics point of view? Cancer Treat Rev 32(8):619-629
3. Collins I, Workman P (2006) New approaches to molecular cancer therapeutics. Nat Chem Biol 2(12):689-700
4. Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsk BM, Palme MH, Habgood GJ, Singer LA, DiPietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 61(3):1013-1021
5. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4(7):1086-1095
6. Perez EA (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 8(8):2086-2095
7. Jimeno A (2009) Eribulin: rediscovering tubulin as an anticancer target. Clin Cancer Res 15(12):3903-3905
8. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA (2008) Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther 7(7):2003-2011
9. Hirata Y, Uemura D (1986) Halichondrins-antitumor polyether macrolides from murine sponges. Pure Appl Chem 58:701-710
10. Bai R, Cichacz ZA, Herald CL, Pettit GR, Hamel E (1993) Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol Pharmacol 44(4):757-766
11. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E (1991) Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem 266(24):15882-15889
12. Fodstad O, Breistol K, Pettit GR, Shoemaker RH, Boyd MR (1996) Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts. J Exp Ther Oncol 1(2):119-125
13. Luduena RF, Roach MC, Prasad V, Pettit GR (1993) Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol 45(2):421-427
14. Hamel E (1992) Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 55(1):31-51
15. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, Jordan MA (2010) Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49(6):1331-1337
16. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res 64(16):5760-5766
17. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89(15):1138-1147
18. Towle MJ, Agoulnik S, Kuznetsov G, TenDyke K, Reardon C, Cheng H, Zheng W, Seletsky BM, Palme MH, Kishi Y, Lewis MD, Yu MJ, Littlefield BA (2003) In vivo efficacy of E7389, a synthetic analog of the marine sponge antitubulin agent halichondrin B, against human tumor xenografts under monotherapy and combination therapy conditions. Proc Am Assoc Cancer Res 44:628
19. McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB (2002) Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 8(7):2035-2043
20. Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH (2005) Marine natural products as anticancer drugs. Mol Cancer Ther 4(2):333-342
21. Alley M, Dykes D, Waud W, Pacula-Cox D, Munro M, Newman D, Sausville E (1998) Efficacy evaluations of halichondrin B in selected xenografts. Proc Am Assoc Cancer Res 26:A1545
22. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH (2009) A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 15(12):4207-4212
23. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, Ashworth S, Rosen LS (2009) Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 15(12):4213-4219
24. Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T (2000) Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 19(27):3078-3085
25. Day BW (2000) Mutants yield a pharmacophore model for the tubulin-paclitaxel binding site. Trends Pharmacol Sci 21(9):321-324
26. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 97(6):2904-2909
27. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY, Martin C (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17(6):1786-1793
28. Kavallaris M, Tait AS, Walsh BJ, He L, Horwitz SB, Norris MD, Haber M (2001) Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res 61(15):5803-5809
29. Gan PP, Pasquier E, Kavallaris M (2007) Class III {beta}-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 67(19):9356-9363
30. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N, Latorre A, Lorusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A (2007) Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer 120(10):2078-2085
31. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G (2005) Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 11(1):298-305
32. Martello LA, Verdier-Pinard P, Shen HJ, He L, Torres K, Orr GA, Horwitz SB (2003) Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 63(6):1207-1213
33. Alli E, Bash-Babula J, Yang JM, Hait WN (2002) Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 62(23):6864-6869
34. Burkhart CA, Kavallaris M, Band HS (2001) The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 1471(2):O1-O9
35. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Dieras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377(9769):914-923
36. Scarpace SL (2012) Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer. Clin Ther 34(7):1467-1473
37. Gitlitz BJ, Tsao-Wei DD, Groshen S, Davies A, Koczywas M, Belani CP, Argiris A, Ramalingam S, Vokes EE, Edelman M, Hoffman P, Ballas MS, Liu SV, Gandara DR (2012) A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California Cancer Consortium trial. J Thorac Oncol 7(3):574-578